Weight Loss Drug Users Often Maintain Loss Even After Stopping Medication, Study Finds
Stopping medications like Ozempic or Mounjaro doesn’t necessarily lead to rapid weight regain, according to a new study published on March 19, 2026, by researchers at the Cleveland Clinic. The findings, which analyzed data from nearly 8,000 patients, offer a more optimistic outlook than earlier clinical trials suggested.
The research, published in the journal Diabetes, Obesity and Metabolism, revealed that many individuals were able to maintain a stable weight for over a year after discontinuing GLP-1 therapies. This success was often linked to restarting treatment, switching to alternative weight management options, or adopting lifestyle changes. This represents significant as obesity is a chronic medical condition and these medications are increasingly used as a treatment option.
Earlier randomized clinical trials had indicated a likelihood of substantial weight regain after stopping these drugs. However, this real-world data suggests a different pattern. Many patients were able to pivot to other treatments or restart therapy, helping them to keep the weight off.
The study focused on semaglutide and tirzepatide, two common GLP-1 medications. Researchers noted the importance of structured lifestyle support in helping patients maintain their weight loss.
The findings offer important context as injectable GLP-1 medications become more widely used, and more people question what happens when they stop taking them outside of controlled clinical settings.
Interest in these medications is growing, with Brazil leading searches for Ozempic and Mounjaro, according to recent reports. Experts caution about potential dangers associated with these drugs, emphasizing the necessitate for careful consideration and medical supervision.
The increasing use of these medications has also raised concerns about potential side effects, including oral health issues, and prompted discussion about appropriate use. Experts have also revealed the BMI at which these drugs may be considered.
data suggests that women aged 40 to 49 are the most frequent purchasers of these weight loss injections.
Healthcare professionals emphasize the importance of evaluation and specialized follow-up for individuals considering these medications. The Senate has also highlighted the need for these medications to be used with proper assessment and monitoring.
